Regenerative Medicine Overview

Principles

Definition

Regenerative medicine is a multidisciplinary field and clinical approach focused on developing therapies to repair, replace, or regenerate damaged or diseased tissues and organs. It utilizes biological principles and technologies, including cell therapy, tissue engineering, and gene therapy, to stimulate the body's intrinsic healing processes and restore lost function.

Ontological type

Clinical Applications

Core Modalities

Mechanisms of Action

Key developments

Key Figures

Transplantation and Marrow Foundations era

D Metcalf [1], associated with The University of Melbourne [3], emerges as a key figure in the transplantation and marrow-centered foundations of this era. His notable contribution, The Growth of Mouse Bone Marrow Cells in Vitro (1966) [6], helped establish ex vivo culture approaches and the concept of marrow-based regeneration essential for bridging laboratory insights to clinical transplantation. E Gutmann [2], affiliated with Princeton University [4] and University of Oxford [5], contributed to foundational nerve regeneration research in this era. Gutmann's contributions include Recovery of fibre numbers and diameters in the regeneration of peripheral nerves [7] and The Rate of Regeneration of Nerve [8], which provided quantitative measures of nerve repair and helped embed rehabilitation-oriented principles into early regenerative strategies.

Cell-based Tissue Engineering era

Arnold I. Caplan [1] emerges as a central figure in this era, with affiliations at Harvard University [3] and Case Western Reserve University [4]. His key contributions include shaping the concept of mesenchymal stem cells as multipotent regenerative progenitors and advancing ex vivo expansion and directed differentiation for osteogenesis and cartilage repair, as illustrated by Mesenchymal stem cells [7], Characterization of cells with osteogenic potential from human marrow [8], and Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy [9]. Catherine M. Verfaillie [2] is also a leading figure in this era, with positions at the University of Massachusetts Chan Medical School [5] and Princeton University [6]. Her work on purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells [11], pluripotency of mesenchymal stem cells derived from adult marrow [10], and multipotent adult progenitor cells from bone marrow differentiating into functional hepatocyte-like cells [12] propelled scalable, clinically relevant regenerative graft strategies during this period.

Paracrine and Reprogramming Therapies era

Shinya Yamanaka [1] is strongly associated with breakthroughs in this era, with affiliations including the University of California, San Francisco [3] and Stanford University [4]. His key contributions in this era include Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors [6] and Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts [7], which established iPSC technology as a transformative, patient-specific cell source for regenerative therapies. Kazutoshi Takahashi [2] is likewise associated with foundational work in this era through positions at the University of California, San Francisco [3] and the Nara Institute of Science and Technology [5]. This work, as captured in Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors [6] and Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts [7], helped drive safer reprogramming approaches and enabled patient-specific, paracrine-based regenerative therapies in this era.